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SUMMARY
By using the DF3 antigen (MUC1) as a molecular marker, previous workers 
reported the detection of tumour cell dissemination by reverse transcriptase 
Polymerase Chain Reaction (rt-PCR) in a pilot study of patients undergoing 
surgery for breast cancer (Brown et al., 1994). The aim of this study was to 
extend these findings and also examine the role of other epithelial markers for 
their suitability as molecular markers for detection of circulating breast carcinoma 
cells using rt-PCR. It was envisaged that this work could be extended to the 
examination of bone marrow and lymph nodes for occult metastases. RNA was 
prepared from MCF-7 breast carcinoma cells and peripheral blood leucocytes of 
healthy female volunteers. This RNA was screened for mRNA of MUC1, CK19 
and CD44 (Exon 8-11) by rt-PCR and the results validated by Southern blots. 
Variable degrees of expression of MUC1 and CD44 (Exon 8-11) were detected in 
normal peripheral blood, rendering these genes non-specific for epithelial cells 
and therefore unsuitable for use as markers to detect circulating breast carcinoma 
cells. Although CK19 mRNA was apparently specific, it was deemed unsuitable 
for use as a marker of circulating breast cancer cells in light of its poor sensitivity. 
These findings prompted an alternative approach to this problem to continue the 
search for the ideal epithelial marker. Therefore, included in this work is RNA 
fingerprinting, a modified Differential Display by the PCR technique which is 
conceived to allow the identification, molecular cloning and sequencing of 
differentially expressed genes. This technique is devised to amplify mRNA and 
display their 3’ termini on polyacrylamide gels. The aim of RNA fingerprinting is 
to identify and characterise the differentially expressed genes in breast cancer 
samples in contrast with normal blood. In this study a total of 18 differentially 
expressed genes (using limited primer combinations) were analysed and found to 
have variable degrees of background expression when used as potential markers. 
However, further work is required to characterise the differentially expressed 
genes using all other primer combinations. This study has cast major doubts on 
the validity of previously published studies in this area. Until a suitable epithelial 
marker for breast cancer is identified, further work to identify tumour cells in 
blood will not be feasible.
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1. INTRODUCTION
1.1 EPIDEMIOLOGY OF BREAST CANCER
1.1.1 INCIDENCE
Breast cancer is the most common form of cancer among women in North 
America, almost all of Europe, Latin America and Australia (Lynn et al., 1995; 
Miller et al., 1991; Boring et al., 1993). It is estimated that the disease will affect 
five million women world-wide in the next decade (Corry et al., 1994). The 
incidence of breast cancer is increasing on average by 1% per year in almost all 
populations, in both industrial and developing countries (Miller et al., 1991; Levi 
et al., 1993).
For the global population as a whole, the incidence and prevalence of breast 
cancer increase with increasing age (Glass et al., 1988; Harris et al., 1992). The 
incidence increases rapidly during the fourth decade of life and continues to 
increase with age after menopause, but less dramatically than before. In Japan and 
other Far Eastern countries, there is a similar pattern of increase in breast cancer 
incidence with increasing age but absolute rates are lower at each age (Harris et 
al., 1992). Despite the increase in incidence rates, the age-adjusted mortality rates 
from breast cancer have proved remarkably stable in the USA. A number of 
factors such as earlier detection and advances in treatment have been suggested to 
account for this trend (Harris et al., 1992).
In Scotland breast cancer is the most common cancer among women. In 1993, 
there were 3004 registrations, accounting for almost 25% of the female cancer 
burden excluding non-melanoma skin cancer (ISD, 1998). For any woman, the 
theoretical risk of developing breast cancer up to the age of 74 is approximately
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8% (Harris et al., 1998). It is also the second cause of death from cancer in 
women, responsible for 1244 deaths in Scotland in 1996.
Whilst in common with all cancers, the prognosis of breast cancer depends upon 
its stage at diagnosis, it is known that approximately 50% of women are still alive 
5 years after their breast cancer was first diagnosed (Black et al., 1993).
1.1.2 AETIOLOGY AND RISK FACTORS
The aetiology of the majority of breast cancer remains unexplained, and it is 
possible that many of the factors responsible are as yet unrecognised. It has been 
observed that large increases in the rates of breast cancer occur among 
populations migrating from Japan to the USA, which indicates that breast cancer 
may be determined by factors other than genetic ones which suggests that the 
potential for prevention exists (Buell et al., 1973). The existence of non-genetic 
determinants of breast cancer is also indicated by the large variations of breast 
cancer among different countries and over time within countries (Armstrong et 
al., 1975; Prentice et al., 1990).
The known hormonal risk factors for breast cancer are related to the cumulative 
effect of oestrogen and possibly progesterone (Henderson, 1991), but controversy 
remains over the contribution of exogenous hormones to the development of 
breast cancer (Helzlsouer et al., 1995). The benefit of hormone replacement 
therapy (HRT) in reducing ischaemic heart disease and osteoporosis and 
improving menopausal symptoms suggest that for the first 10 years of use the 
overall effects of therapy on morbidity and mortality are likely to be beneficial 
(Helzlsouer et al., 1995), but concerns about HRT centre on the risk of
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endometrial cancer and breast cancer, especially after long-term use (more than 
10 years). There is also considerable uncertainty about the relationship between a 
woman's risk of developing breast cancer and the length of time she receives HRT 
(Grodstein et al., 1997, Brinton et al., 1997).
A family history of breast cancer is known to be an important risk for the disease 
(Claus et al., 1990) and although most of breast cancers are sporadic, 
approximately 5% are familial (Xu et al., 1996). The existence of a breast cancer 
susceptibility gene was demonstrated by genetic linkage analysis of breast cancer 
families (Hall et al., 1990). This gene was later named BRCA1 (Solomon et al., 
1992) and preliminary reports suggest that it is a large gene and the mutations are 
not confined to particular regions. The susceptibility to breast cancer is generally 
inherited as an autosomal dominant with limited penetrance (Skolnick et al.,
1992). About a third of familial cases are thought to be due to mutation in the 
BRCA1 gene on the long arm of chromosome 17. Some inherited BRCA1 
mutations seem to be associated with only a modestly increased risk of breast 
cancer. A second hereditary breast cancer locus, BRCA2, has been identified in 
the long arm of chromosome 13 (Xu et al., 1996). In addition, a few cases arise 
from mutations in the p53 gene on the short arm of chromosome 17 (Hoskins et 
al., 1994).
Many families affected by breast cancer show an excess of ovarian, colon, 
prostatic and other cancers attributable to the same inherited mutation. Patients 
with bilateral breast cancer, those who develop a combination of breast cancer 
and another epithelial cancer, and women who get the disease at an early age are 
most likely to be carrying a genetic mutation that has predisposed them to 
developing breast cancer. Most breast cancers that are due to a genetic mutation
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occur before the age of 65, and a woman with a strong family history of breast 
cancer who is still unaffected by the age of 65 has probably not inherited the 
genetic mutation.
A woman’s risk of breast cancer is doubled if she has a first degree relative 
(mother, sister, or daughter) who developed the disease before the age of 50, and 
the younger the relative when she developed breast cancer the greater the risk 
(10% cumulative risk), this risk approaches 5% (close to the population risk) if 
the first-degree relative was older than 50 years at diagnosis. The risk increases 
by four to six times if two first-degree relatives develop the disease (McPherson 
et al., 1994).
Many other risk factors for breast cancer have also been identified, such as early 
menarche (Kampert et al., 1988), late menopause (Trichopoulos et al., 1972), 
nulliparity or late age at birth of first child (White, 1987; MacMahon et al., 1970) 
and a history of benign breast disease (Dupont et al., 1985). Women with severe 
atypical hyperplasia have a four to five times higher risk of developing breast 
cancer than women who do not have any proliferative changes in their breasts 
(Dupont et al., 1985). Women with this change and a family history of breast 
cancer have a nine fold increase in risk. Women with palpable cysts, duct 
papillomas, sclerosing adenosis, and moderate or florid epithelial hyperplasia 
have slightly higher risk of breast cancer (1.5-2 times) than women without these 
changes, but this increase is not thought to be clinically significant (Dupont et al., 
1985).
Unfortunately it has not been possible, to date, to utilise the known risk factors to 
allow the identification of the small, high-risk group that accounts for a large 
proportion of women with the disease (Harris et al., 1992). Progress towards the
identification and subsequent modification of risk factors for the prevention of 
breast cancer has so far been disappointing, and prevention currently depends 
upon the artificial manipulation of hormones and growth regulators that underly 
the known risk factors. Although the preliminary results of the Breast Cancer 
Prevention Trial (BCPT) indicate a 45% reduction in breast cancer incidence with 
prophylactic use of tamoxifen (Pritchard, 1998), other similar chemoprevention 
trials (Veronesi et al., 1998; Powles et al., 1998) have failed to confirm BCPT 
results which are nevertheless consistent with 39% preventive effect of 5 years of 
tamoxifen reported by the Early Breast Cancer Trialists Collaborative Group 
(EBCTCG). The findings of The International Breast Cancer Intervention Study 
(IBIS) are still awaited to clarify the preventive benefits of tamoxifen.
1.2 PROGNOSTIC FACTORS OF BREAST CANCER
Prognostic factors are clinical and pathological features that give information in 
estimating the likely clinical outcome of patients suffering from cancer. Several 
histopathological, biochemical and immunological variables have been reported 
to be useful prognostic factors. Since breast cancer is a heterogenous disease and 
metastasis a complicated process, no single prognostic factor predicts whether a 
patient will develop recurrence. Most studies on prognostic factors are 
retrospective, with small numbers of patients and often insufficient follow-up to 
allow true determination of the effect of a prognostic factor on relapse or survival. 
A host of prognostic factors are being evaluated to determine their ability to 
predict recurrence in node-negative breast cancer . Tumour size, axillary lymph 
node status, histologic grade and the hormonal receptor status are established
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prognostic factors for breast carcinoma (Schnurch, 1998).
Clinical variants also have a bearing on prognosis and it is suggested that patients 
with small node-negative tumours have an excellent prognosis (Rosen et al.,
1993) and the larger the tumour, the worse the prognosis (Fisher et al., 1969). 
Breast carcinoma occurring during pregnancy or lactation is generally considered 
to have a poor prognosis (Wile et al., 1989).
Sinus histocytosis or reactive hyperplasia of lymph nodes has been shown in 
some series to be associated with good outcome. The 5 year survival rate is likely 
to be 80% if three or less lymph nodes are involved, This figure drops to 30% 
when four or more lymph nodes are involved.
Nodal status remains the most powerful determinant of survival in breast cancer 
patients and a quantitative guide to prognosis from histopathology is best 
obtained by grading. Some tumour types have an especially good prognosis, 
particularly “medullary” carcinoma which frequently shows heavy infiltration of 
the tumour with lymphocytes.
The most widely used histological grading system for breast cancer in the UK is 
based on that of Bloom and Richardson (1957) and modified by Elston (1987). In 
this system a separate score of 1-3 is given for each of three features - tubular 
formation, nuclear pleomorphism and the number of mitoses per 10 high-power 
microscopic fields. A total score of 3-5 indicates grade I (well-differentiated 
carcinoma), 6-7 indicates grade II and 8-9 grade III (poorly-differentiated 
carcinoma). There is good correlation with prognosis: Grade I tumours are 
associated with significantly better survival than grade II (Elston et al., 1982). 
Figure 1 shows these prognostic factors have been combined in the Nottingham 
prognostic index (Haybittle et al., 1982), which, in addition to providing useful
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Nottingham Prognostic Index (NPI)
Index 0.2 x Size (cm) + Grade + Stage
Grade:
1 = tubular, cribriform, mucoid
2 = medullary, lobular
Stage: (refers to lymph node status)
1 = negative
2 = <4
3 =>4
Index:
<3.4 = low
3.41 - 5.4 = medium 
>5.4 = high
Score of 3 or less is associated with excellent prognosis while a score of more 
than 6 is associated with less than 20% 5-year survival (Todd et al; 1986).
Figure I
prognostic information, also selects out high risk patients for adjuvant systemic 
treatment. Another prognostic index based on tumour size, lymph node status and 
mitotic activity index is advocated by Baak and colleagues (van der Linden et al., 
1987).
The hormonal receptor status is the best known predictive factor with regard to 
response to hormonal treatment. It correlates with both longer disease-free 
interval and prolonged survival time (Preece et al., 1982; Rayter, 1991).
There are many biological factors such as kinetic indices, over-expressed growth 
factor receptors, mutated tumour-suppressor genes and enzymes that may play a 
role in the metastatic process (Silvestrini et al., 1996; Gilchrist et al., 1993; 
Seshadri et al., 1993; Allred et al., 1993; Friedrichs et al., 1993; Weidner et al., 
1992; Maggiora et al., 1998).
S- phase fraction of the tumour appears to correlate well with the risk of relapse, 
but is subject to variation between laboratories and may not be independent of 
tumour grading by the pathologist (Hedley et al., 1987).
The lysosomal acidic protease cathepsin D is another potential prognostic 
indicator (Winstanley et al., 1993). This enzyme is present in high levels in 
cancer cells and its secretion from breast cancer cells is stimulated by oestrogen 
(Rochefort, 1990).
The prognostic value of over-expression of the HER2/neu gene product in both 
node-positive and node-negative breast cancers has been conflicting (Seshadri et 
al., 1993). In a study of 254 node-negative tumours, Gasparini (1994) 
demonstrated that microvessel density was a stronger predictor of relapse-free 
survival than tumour lymphatic invasion, p53 expression, or tumour size. Acenero 
(1998) established vascular density to be a significant prognostic indicator in both
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node-negative and node-positive patients. However, p53 protein over expression 
was reported to be an independent predictor of reduced disease-free survival in 
node-positive and ER-positive patients but not in node-negative or ER-negative 
individuals (Levesque et al., 1998).
Determination of c-erbB-2 levels was reported to be an important biomarker to 
assess the extent of disease spread in the lymph nodes as well as a prognostic 
indicator for disease-free survival in patients who receive chemotherapy (Mehta 
et al., 1998).
DNA-RNA contents in breast cancer were found to be independent prognostic 
factors. Hara et al. (1998) found that high RNA index of more than 4.0 correlates 
significantly with poorer prognosis.
1.3. MANAGEMENT OF BREAST CANCER
The diagnosis of breast cancer is made by clinical examination, mammography 
and/or ultrasound, fine needle aspiration and core biopsy.
Local treatment to the breast
Breast-conserving surgery, combined with radiotherapy and systemic therapy, is 
now considered to be more appropriate than radical mastectomy for the majority 
of women with early stages of breast cancer, and is associated with survival rates 
comparable to those following mastectomy (Veronesi et al., 1990; Harris et al., 
1992; Fisher et al., 1995).
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Local treatment to the axilla
The axilla may either be surgically cleared of all nodes or alternatively node 
sampling may be performed. A minimum of four nodes sampled is required to 
adequately determine the pathological nodal status (Forrest et al., 1995). There is 
no need for postoperative radiotherapy if the axilla has been cleared. However, if 
sampled nodes are involved by tumour, radiotherapy may be indicated to control 
presumed residual disease in the axilla.
Adjuvant radiotherapy
Radiotherapy to the breast after conserving surgery significantly reduces the risk 
of local recurrence (Veronesi et al., 1993; Liljegren et al., 1994; Fisher et al., 
1995). Although radiotherapy after mastectomy reduces the risk of local 
recurrence, it has very little effect on overall survival due to increased cardiac 
morbidity (Cuzick et al., 1994). However, in premenopausal women receiving 
adjuvant chemotherapy, postmastectomy radiotherapy appears to significantly 
improve survival (Overgaard et al., 1997; Ragaz et al., 1997).
After axillary sampling, the axilla should only be irradiated if node positive or 
inadequately sampled. If there is no axillary node involvement by tumour, 
radiotherapy confers no additional benefit in term of local recurrence and 
significantly increases the risk of morbidity (Dewar et al., 1987; Forrest et al., 
1995).
Adjuvant systemic therapy
The objective of systemic therapy is to reduce the growth potential of 
micrometastases. The systemic treatment comprises cytotoxic and endocrine
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therapies. Adjuvant systemic therapy improves relapse free survival and overall 
survival in all age groups (EBCTCG, 1988; 1996).
Cytotoxic chemotherapy is used as adjuvant treatment following primary surgery 
on the primary tumour and treatment of advanced or metastatic breast cancer. 
Ovarian ablation improves long-term survival in women aged under 50 with early 
breast cancer (EBCTCG, 1996). Ovarian suppression can be carried out medically 
using LHRH-A or by radiotherapy or surgery. Oophorectomy was the first form 
of endocrine therapy to be used for breast cancer treatment, a century ago 
(Beatson et al., 1896), and adrenalectomy and hypophysectomy were introduced 
in the early 1950s (Huggins et al., 1952; Luff et al., 1953). Since then, systemic 
endocrine drugs, such as tamoxifen, have been successfully used in the treatment 
of advanced breast cancer (Boring et al., 1993).
Combination chemotherapy and tamoxifen are standard adjuvant therapies for 
most women with node-positive breast cancer and some women with node­
negative breast cancer. However, prognostic factors that identify women with 
node-negative disease at high risk of recurrence are not yet available for the 
majority of patients (Gasparini et al., 1993).
Cytotoxic chemotherapy is associated with severe side-effects such as alopecia, 
weight gain, fatigue and can compromise the immune system (Hafstrom et al., 
1990). However, the short-term use of chemotherapy in the adjuvant setting is 
generally well tolerated. Although some improvement in tolerability of 
chemotherapy has occurred since the introduction of intermittent, pulsed therapy 
and autologous bone marrow support techniques, the overall toxicity of 
chemotherapy is still considerable, particularly in postmenopausal women (Harris 
et al., 1992).
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Despite major advances in adjuvant therapy, improvement in survival has been 
disappointingly small. Fisher (1997) reported a significantly better disease-free 
survival in patients with node-negative, ER-positive tumours who received 
chemotherapy plus tamoxifen than those who received tamoxifen only. Targeting 
patients appropriately for adjuvant therapy is currently based on clinico- 
pathological prognostic factors. Nodal status has been established as the most 
important prognostic indicator and it is suggested that a level I and level II 
axillary lymph node dissection be performed for all early invasive breast cancer 
(Cobum et al., 1995). The use of a prognostic score was recently proposed to 
replace routine axillary lymph node dissection as a means of identifying patients 
who benefit from adjuvant therapy (Menard et al., 1994). Sentinel node biopsy 
has been suggested as an alternative to axillary node dissection for clinical stage I 
breast cancer (Giuliano et al., 1994). This seems to be an attractive alternative, 
but its validity must be prospectively verified before it is universally adopted.
The use of systemic therapy early in the course of malignant disease has been 
shown to influence survival in some common cancers, such as those of breast 
(EBCTCG, 1994) and colon (Moertel et al., 1990; Riethmuller et al., 1994). The 
improvements are, however of limited scale. This results in exposure of some 
patients to unnecessary toxicity as well as making evaluation of the treatment 
difficult.
Recent interest has focused on developing laboratory methods to identify 
disseminated tumour cells in the circulation. This may identify a subgroup of 
patients suitable for adjuvant systemic chemotherapy. The identification of 
specific molecular markers may allow a more rational allocation of such adjuvant 
therapy. Apart from the prescription of therapy to a poor prognosis sub-group, the
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molecular identification of residual disease may also prove useful in determining 
alternative end points. The practical problem of continuing with ineffective 
therapy over long periods may be more readily identified if reliable markers of 
tumour persistence can be identified.
1.4 DETECTION OF CIRCULATING CANCER CELLS
There is increasing emphasis on the detection of circulating cancer cells in the 
peripheral blood. This has potentially significant therapeutic and prognostic 
implications. It may be feasible to select suitable patients to assess their response 
to systemic therapy, and also to identify residual or recurrent disease after 
potentially curative treatment.
Animal studies have demonstrated that manipulation of the primary tumour 
facilitates tumour cell spread via the blood stream and may promote metastases. 
The “no touch” isolation technique reported by Turnbull (1967) in patients with 
colon cancer has provided the only clinical evidence that surgical manipulation of 
primary tumours may precipitate tumour cell shedding. Tyzzer et al. (1913) 
demonstrated an increase in the number of pulmonary metastases by manipulating 
transplanted breast tumours in mice. The hypothesis that operative handling of 
malignant neoplasms facilitates tumour cell dissemination into the blood stream 
has been investigated by many workers using different methodologies.
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1.5 METHODS OF DETECTION OF CANCER CELLS
Several workers have attempted to identify circulating tumour cells in various 
malignancies (Choy et al., 1996; McCulloch et al., 1995; Brown et al., 1995; 
Smith et al., 1991; Burchill et al., 1994; 1995). Various techniques including 
morphology, flow cytometry and cytogenetics have been used to detect 
disseminated tumour cells at a level of 1 in 100, but these have limited sensitivity 
and specificity and are time-consuming (Diel et al., 1992; Frank et al., 1990; 
Johnson et al., 1995).
1.5.1. CYTOLOGY
Historically, conventional cytology has been the method used to detect circulating 
tumour cells. Difficulties in distinguishing tumour cells from plasma cells and 
atypical mononuclear cells, occasionally found in normal blood, has lead to a 
variation in the interpretation of the morphological features of malignant cells.
1.5.2. FLOW CYTOMETRY
Flow cytometry is a method of quantitating components or structural features of 
cells primarily by optical means. Although it makes measurement on one cell at a 
time, it can process thousands of cells in a few seconds. Since different cells can 
be distinguished by quantitating structural features, flow cytometry can be used to 
count cells of different types in a mixture.
Flow cytometry provides valuable information regarding cellular DNA content 
and nuclei (ploidy), which are isolated from single cell suspensions and stained 
with fluorescent dye. The sample is run through a cytometer, which uses a laser 
or mercury light source to excite the fluorescently labelled nuclei. The emission is
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recorded on a DNA histogram, which recognises aneuploid and diploid cells as 
separate peaks. Ploidy is quantified as the DNA index, a measure of the ratio of 
the mean DNA content of the test sample cell to that of the diploid controls. DNA 
index of greater than 1 is considered aneuploidy. Determination of ploidy status is 
useful prognostically in a variety of solid tumours such as ovarian cancer where 
ploidy status was found to be a significant independent prognostic factor. 
Aneuploidy also correlates with a worse prognosis in many solid tumours 
including melanoma and breast. Suzuki et al. (1997) suggested strict follow-up of 
aneuploid parathyroid adenomas, as there is increase in premalignant potential as 
determined by DNA flow cytometry.
Flow cytometry can also be used to estimate the tumour proliferative activity, 
which is a measure of the percentage of cells actively proliferating. The histogram 
is used to calculate the cell cycle distribution and the percentage of cells in the S 
(synthesis) phase.
Coustan-Smith et al. (1998) investigated minimal residual disease in bone- 
marrow aspirates from children with treated acute lymphoblastic leukaemia 
(ALL) and claimed a powerful prediction of relapse in children with ALL using 
multiparameter flow cytometry.
The value of flow cytometry in prognostic determination of breast cancer is 
unclear. Several studies have demonstrated a poorer prognosis for patients with 
node-negative aneuploid tumours as compared with diploid tumours, whereas 
others have been unable to assign ploidy a role as an independent prognostic 
factor. However, in patients with stage II and III disease, aneuploidy and a high 
S-phase fraction have strongly correlated with diminished disease-free survival 
(Hurwitz et al., 1992).
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1.5.3. IMMUNOCYTOCHEMISTRY
This technique allows cell-specific (as opposed to Western blot) localisation of 
protein in thin tissue sections, using antibodies directed against specific peptide 
sequence. The technique can be used alone, but is a much more powerful tool 
when employed in conjunction with other techniques such as in situ hybridisation. 
Historically, immunocytochemistry started in 1941 when Coon identified 
pneumococci using a direct fluorescent method. This was followed by the indirect 
method, the addition of'horsedish' peroxidase anti-peroxidase technique of 1979 
and the use of Avidin and Biotin complex in the early 1980s (Burnet et al., 1997). 
Initial applications were directed primarily to the identification of cell and sub- 
type (lineage related markers). Most recently immunohistochemical markers have 
been described that show great promise in determining tumour prognosis at a very 
early stage of tumour development, independent of stage and grade (Taylor et al., 
1997).
Immunocytochemistry which may detect one tumour cell in 105 normal cells 
(Molino et al., 1991; Osborne et al., 1991) has also been used in an attempt to 
detect circulating breast carcinoma cells peri-operatively (Glaves et al., 1988; 
Choy et al., 1996; McCulloch et al., 1995). This technique is, however dependent 
upon the availability of antibodies to tumour-associated cell-surface antigens and 
may be subject to false positives when antibodies cross-react or tumour antigens 
are presented on host immune cells (Hydermann and McCartney, 1985; Leather 
et al., 1993) combined immunocytochemistry and conventional cytology to detect 
circulating malignant epithelial cells in patients with colorectal cancer in the peri­
operative period.
The K-ras gene mutation has been used to detect circulating colorectal cancer
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cells by an immunobead-PCR assay, but this approach is limited because of the 
low frequency of the gene mutations (30%) in these tumours (Hardingham et al.,
1995). No similar specific mutations are known for breast cancer.
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1.5.4 PCR
The polymerase chain reaction (PCR) is a technique for in vitro amplification of 
specific sequence of either DNA or RNA using two oligonucleotide primers that 
hybridise to opposite strands and flank the region of interest in the target DNA. A 
repetitive series of cycles involving template denaturation, primer annealing, and 
the extension of the annealed primers by DNA polymerase results in the 
exponential accumulation of a specific fragment whose termini are defined by the 
5’ ends of the primers. Because the primer extension product synthesised in one 
cycle can serve as a template in the next, the number of target DNA copies
approximately doubles at every cycle. Thus, 20 cycles of PCR yields about a
20million-fold (2 ) amplification. The PCR method was described by Kary Mullis 
and colleagues at the Cetus Corporation (Mullis et al., 1986; 1987) and originally 
applied by a group in the Human Genetics Department at Cetus to amplify 
human-globulin DNA and in the prenatal diagnosis of sickle-cell anaemia (Saiki 
et al., 1985; 1986; Embury et al., 1987). A schematic diagram of the rt-PCR 
method is shown in Figure 2.
! PCR can potentially detect one cell in 106 normal cells (Mullis et al., 1986; Saiki
I et al., 1985). It therefore has the necessary sensitivity to detect a small number of
|
i  tumour cells in peripheral blood by amplification of specific DNA sequences.
i
I
The first tissue-specific enzyme used as a molecular marker was tyrosinase, 
expressed by melanocytes as part of the melanin synthesis pathway. Since normal 
melanocytes are not normally found in peripheral blood, detection of tyrosinase 
transcription in peripheral blood by RT-PCR should demonstrate the presence of 
circulating melanoma cells (Smith et al., 1991). Using this technique it was 
possible detect one melanoma cell in at least 105 normal cells.
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Tumour-specific DNA sequence abnormalities have been identified mainly in 
haematological malignancies such as acute lymphoblastic leukaemia (Yamada et 
al., 1990) where RT-PCR has been used to aid in the diagnosis or follow-up of 
patients with the disease. When there is a tumour specific sequence, PCR has 
been shown to detect one malignant cell in up to 10 normal cells (Mattano et al., 
1992; Fabrega et al., 1993; Alkan et al., 1993; Cross al., 1993; Datta et al., 1994; 
Gerhard et al., 1994; Negrin and Peasando, 1994; Luppi et al., 1996; Mori et al.,
1996). This increases sensitivity of detection by an order of magnitude when 
compared with immunocytochemistry.
For solid tumours however, tumour-specific DNA sequence abnormalities are 
uncommon and tissue specific RNA has been used as a molecular marker for rt- 
PCR (Smith et al., 1991; Burchill et al., 1994) since epithelial tissues are not 
normally present in peripheral circulation. The sensitivity of tumour cell detection 
by rt-PCR was greater than that of immunocytochemistry for CEA or cytokeratins 
(Gerhard et al., 1994).
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1.6 CANDIDATE GENES
1.6.1 PEM
The human polymorphic epithelial mucin (PEM) is an extensively glycosylated 
high molecular weight mucin glycoprotein (250 - 500 kDa). Purified mucins from 
different normal and malignant tissues demonstrate heterogeneity in carbohydrate 
composition and structure (Shimizu and Yamauchi, 1982; Gendler et al., 1991; 
Seregni et al., 1997). Monoclonal antibodies have been used to identify many of 
the clinically useful epitopes and to develop a serum assay that detects and 
quantifies mucin levels in blood and other body fluids and have been proven to be 
of clinical diagnostic value. Some of these antibodies recognise epitopes exposed 
on tumour mucin but not on corresponding normal cell populations (SM-3 and 
B72.3), whereas others recognise epitopes exposed on mucin produced by normal 
and/or malignant cells of several organ sites (DnPan 2 and CA 19-19).
The human DF3 breast carcinoma - associated antigen (MUC1) gene is a core 
protein of PEM and is uniformly and highly expressed apically by glandular 
epithelium of normal and malignant human mammary epithelium (Lancaster et 
al., 1990; Ho et al., 1993) and rarely expressed in non-epithelial tissues (Zotter et 
al., 1988). It is also found in the cytosol and on the cell membrane of 
adenocarcinomas of ovary and lung and mesothelial cells (Ho et al., 1993; 
Hilkens, 1988).
The splicing pattern and nucleotide sequence of MUC1 mRNA expressed in 
ovarian cell lines (CaOV-3, OVCAR-3 and SKOV) is the same as that of breast 
and pancreatic cell lines with a single nucleotide exception (Stem et al., 1992). 
Members of the MUC1 family of mucins isolated from different tissue types have 
been shown to differ in biochemical properties and immunological reactivity.
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However, the molecular basis of the alterations that occur in mucins during the 
pathogenesis of different diseases is poorly understood.
Studies that demonstrate expression of more than one mucin core protein by 
different adenocarcinomas and their normal tissue counterparts suggest that 
expression of distinct arrays of core proteins may be associated with tumours 
from distinct organ sites (Yonezawa et al., 1991; Devine et al., 1991; Devine and 
Mckenzie, 1992; Ogata et al., 1992; Seregni et al., 1996; Kim, 1998). 
Hollingsworth (1994) reported that most pancreatic tumour cell lines express 
MUCI and/or MUC4, but extremely low levels of MUC2 and almost undetectable 
levels of MUC3 mRNA whereas colon tumour cell lines generally express high 
levels of MUC2 and/or MUC3, but rarely express significant levels of MUC4. 
These studies suggest that tumour-derived mucin detected in serum may show a 
core protein composition distinct from serum mucin derived from normal tissues. 
MUCI is expressed in the tissue of 90% of cases of breast cancer (Papadimitriou 
et al., 1993). It has been detected in patients’ serum and has been shown to be 
increased in metastatic disease (Abe et al., 1993).
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1.6.2 CYTOKERATINS
Intermediate filaments (diameter, about 10 nm) are primary components of 
mammalian cell cytoskeleton and constitute a multigene family of related 
proteins distinguished by cell type-specific expression (Nagel et al., 1988).
The cytokeratins (CKs) comprise some 20 different isotypes and are 
predominantly expressed in epithelial cells where they show strict lineage- and 
differentiation- associated patterns of expression (Moll et al., 1982; Sun et al., 
1984). They have also been detected in many normal and neoplastic non- 
epithelial cell types using immunohistochemical techniques (Traweek et al., 
1993).
Malignant cells generally retain the intermediate filaments of their progenitor cell 
type and consequently CKs have been used to characterise neoplastic cells of 
epithelial origin (Osborn and Weber, 1983; Cooper et al., 1985; Lane et al., 
1990). Carcinomas are characterised by cytokeratins, sarcomas of muscle cells by 
desmin, non muscle sarcomas by vimentin and gliomas by glial fibrillary acidic 
protein (Osbom and Weber, 1983).
Cytokeratin 19 (CK19) is synthesised mainly in embryonic and adult simple 
epithelia, but has also been found in stratified epithelia as well. CK19 is the 
smallest known keratin and is remarkable in that, unlike all other keratins, it does 
not have a designated partner for the formation of filaments, implying that 
regulation of its expression is different from other keratin-encoding genes 
(Lussier et al., 1990).
The cytokeratins are primarily expressed in epithelial cells (Moll et al., 1982). As 
the specificity of expression of intermediate filaments proteins is retained in 
malignant tumours, they are suitable as tumour markers (Moll, 1993). CK19 has
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been reported as a specific and sensitive marker for detection of breast carcinoma 
cells in peripheral blood and the bone marrow of patients with breast cancer by rt- 
PCR (Datta et al., 1994). CK19 has been shown to be expressed in the tissue of 
90% of invasive breast cancer (Papadimitriou et al., 1993).
1.6.3 CD44
CD44 is a widely expressed cell surface glycoprotein that serves as an adhesion 
molecule in cell-substrate and cell-cell interactions, including lymphocyte 
homing, cell migration, and metastasis (Haynes et al., 1991; Matsumura and 
Tarin, 1992; MacKay et al., 1994). It is thought to be associated with aggressive 
histological features in breast cancer. It has also been implicated in conferring 
metastatic potential to rat carcinoma cells ( de la Torre et al., 1995).
CD44 is a transmembrane glycoprotein occurring in several isoforms with 
different extracellular regions. The various transcripts are encoded by one gene 
locus containing 20 exons, of which at least 10 can be alternatively spliced in 
nascent RNA (Fox et al., 1994). Isoforms encoded by the variant exons (termed 
CD44v) are highly restricted in their distribution in non-malignant tissue as 
opposed to the standard form of CD44 (CD44s) abundant in many tissues. 
MacKay et al. (1994) used antibodies specific for variants CD44v4, CD44v6 and 
CD44v9. They found that most epithelia expressed CD44v9, whereas expression 
of CD44v4 and CD44v6 was more tightly restricted. These variant isoforms were 
most abundantly expressed in the generative cells of epithelia such as the 
myoepithelial cells of the mammary gland.
Specific variant isoforms containing exon 6v have been shown to render non­
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metastatic rat tumour cells to have metastatic potential (Hofmann et al., 1991). 
Based on the prominent role in rat metastasis formation, CD44v isoforms were 
suggested to be involved in human tumour progression. Correlations between 
prognosis and expression of CD44 have been reported for gastric and colon 
carcinoma, non-Hodgkin's lymphoma, and more recently for breast carcinoma 
(Kaufmann et al., 1995).
CD44 (Exon 8-11) was used as a potential marker since a CD44 variant encoding 
these sequences has been shown to be expressed in human colorectal and breast 
cancers and has been implicated in the induction of the metastastatic phenotype in 
rat pancreatic tumour cells (Gunthert et al., 1991; Hofmann et al., 1991; Delatorre 
et al., 1995). CD44 splice variants specific to breast malignant tumour cells have 
also been described by Matsumura (1992) who reported that peripheral blood 
leucocytes contained only the standard form of CD44 mRNA, although others 
have reported traces of these splice variants in blood (Fox et al., 1994).
1.7 RNA FINGERPRINTING
This is a modified differential display technique, which has been developed as a 
tool to detect and characterise altered gene expression in eukaryotic cells. The 
basic principle is to systematically amplify messenger RNA and then distribute 
their 3’ termini on a denaturing polyacrylamide gel. The technique was applied to 
compare mRNA from normal blood and tumour-derived human mammary 
epithelial cells. Complementary DNA fragments corresponding to apparently 
differentially expressed mRNA are recovered and sequenced.
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1.8 AIMS
The aim of the work presented here was to examine the DF3 antigen, CK19 and 
CD44 (E8-11) as suitable molecular markers for the detection of circulating 
breast carcinoma cells.
This work has also included the RNA fingerprinting technique which is 
conceived to allow the identification and molecular cloning and sequencing of 
differentially expressed genes. The aim of the latter part of this work was to 
isolate sequence tags which are expressed in all or a majority of malignant breast 
tumours but not in any normal peripheral blood samples.
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2 METHODS 
2.1 Tissue culture
Aseptic manipulation was observed using sterilised glassware in a class II 
microbiological safety cabinet with vertical airflow.
2.1.1 Cell lines and maintenance
MDA and MCF7 human breast carcinoma cells express CK19 (Moll et al., 1982) 
Both lines were maintained in RPMI-1640 (GIBCO BRL) supplemented with 
10% foetal calf serum, 0.2% sodium bicarbonate, 2 mM sodium pyruvate and 4 
mM glutamine. Cells were grown as monolayers and were passaged every 4 days 
at 5 x 105 cells/ml in Nunclon tissue culture grade flasks and kept at 37 °C in 5% 
CO2 , 95% O2 . Cells were stored by freezing in RPMI with 10% di-methyl 
sulphoxide (DMSO) in 1ml cryotubes at -70° C and were then maintained in 
liquid nitrogen.
2.1.2 Mycoplasma testing
Cells were tested periodically for the presence of mycoplasma. The cells to be 
tested were pelleted by centrifugation at 1500 rev/min for 5 min in an MSE bench 
centrifuge. The cell-free supernatant was then placed in a sterile tissue culture 
grade petri dish (Nunclon), 2 ml of fresh medium was added, and 2 x 105 NRK49 
fibroblast were seeded into the dish. These cells are known to be mycoplasma- 
free. The dish was incubated at 37 °C in a humidified incubator at 5% CO2 , 95% 
O2 for 3 days. At the end of the incubation period the cells were fixed with a 
fixative (1 volume of glacial acetic acid : 3 volumes of ethanol) for 5 min. The 
fixative was then removed and the cells air dried. Hoechst 33258 stain was
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prepared from a 1 mg/ml stock by diluting 1:20000 in phosphate buffered saline. 
This solution was poured onto the fixed cells and incubated at room temperature 
for 10 min. The stain was removed and cells were washed two times in water. The 
cells were viewed by fluorescence microscopy using a water immersion lens. 
Hoechst 33258 is a fluorescent stain for DNA. If the cells were mycoplasma-free, 
only the cell nucleus fluoresced; however if the original cells were mycoplasma 
infected fluorescence was also detected in the cytoplasm of the NRK49 cells.
2.2 DNA methodology
2.2.1 Gel electrophoresis of PCR products
rt-PCR products were analyzed by 2% agarose gel electrophoresis (5 volts/cm for 
2-3 hours) stained with ethidium bromide (0.5 pg/ml). A 100 bp DNA ladder or
c()Xl 74 RF DNA/Hae III Fragments (Gibco BRL) were used as markers for
comparison. The gel was then photographed under ultraviolet illumination using a 
Polaroid camera.
2.2.2 Southern blot analysis of DNA
PCR products were transferred from ethidium-stained agarose gels onto nylon 
membrane (Hybond N+, Amersham,UK.) by overnight capillary transfer using 
0.4M NaOH (Maniatis et al., 1989). Filters were then placed in roller bottles 
(Hybaid, UK.) and prehybridised at 65°C for 4-6 hours in 20 ml of 
prehybridisation buffer containing 6X SSC (0.9M NaCl, 0.9M Na citrate), 10X 
Denhardts (0.2% (w/v) each of ficol, polyvinylpyrrolidone and bovine serum 
albumin) and 100 pl/ml denatured sonicated salmon sperm DNA.
Prehybridisation buffer was removed and hybridisation fluid containing IX 106
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cpm/ml of [32p] y ATP labelled oligonucleotide probe complementary to an 
internal sequence in the PCR product for MUCI, and hybridisation was continued 
for further 12-18 h (For CK19 and CD44 the downstream primers were used as 
probes). Oligonucleotide hybridisation temperature was calculated from an 
imperical formula Ti + 4X (G or C) + 2X (A or T) - 5°C and hybridisation was 
continued for further 12-18 hours.
Filters were then washed at Ti for 60 minutes in a buffer containing 6X SSC, 
0.1% SDS and for 5 minutes in the same buffer at Ti + 5°C. At the completion of 
washing, filters were placed in polythene bags and exposed to X-ray film (Kodak 
XAR-2 or equivalent) in cassettes with intensifying screen and exposed at -70°C 
for 12-36 hours. Films were developed in a Kodak M7A automatic X-ray 
processor.
2.2.3 Preparation and quantitation of oligonucleotides
Primers were designed on an Applied Biosystem model 381A DNA synthesizer. 
5’ trityl groups were removed on the synthesizer before the oligonucleotide was 
eluted from the column in concentrated (29%) ammonia solution for 1.5h at room 
temperature. Oligonucleotide primers were deprotected by incubation in ammonia 
in a sealed glass vial overnight at 55°C. The deprotected primers were then 
purified using the COP cartridge method (Cruachem Ltd., Glasgow, Scotland). 
Oligonucleotides were suspended in water and quantified spectrophotometrically. 
An A260 value of 1 was taken to equal 33mg/ml of oligonucleotide. A ratio of 
A260/A280 was approximately 1.8 when sufficently purified.
34
2.3 RNA METHODOLOGY
2.3.1 Collection of samples
Peripheral blood samples were obtained from healthy female volunteers aged 
between 18 and 48 years. The first 5 ml were discarded and the second 5 ml were 
collected in potassium EDTA bottles and promptly transported to the laboratory 
at 4°C for immediate processing.
2.3.2 RNA extraction, purification & quantification
In preparation and handling of RNA, scrupulous precautionary steps were taken 
in order to avoid degradation by contaminating Rnases which may yield spurious 
results. All techniques were carried out wearing gloves, tubes and solutions were 
pre-cooled on ice and centrifugation carried out at 4°C and aerosol-resistant,
Dnase- and Rnase-ffee tips were used for all manipulations. All tubes were also 
pre-treated with diethylpyrocarbonate (DEPC), an irreversible inhibitor of 
RNases. The tubes were immersed in a solution of 0.1% (v/v) DEPC for a 
minimum of 2 hours in a fume hood, the solution decanted off and the tubes 
autoclaved followed by drying in an oven at 80°C. The tubes were subsequently
stored in sealed DEPC-treated containers. Distilled water was also DEPC-treated: 
0.1% (v/v) solution was prepared, incubated overnight and autoclaved.
Total cellular RNA was extracted from cell lines and normal whole blood using 
RNAzol™ B (Biogenesis Ltd.) according to the manufacturer’s instructions. The 
concentration of aqueous solutions of RNA was measured 
spectrophotometrically. An A260 value of 1 was taken to equal 40 (ig/ml RNA 
and A260 /280 ratio of 1.9 represented essentially pure RNA.
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2.3.3 Reverse transcriptase-polymerase chain reaction (rt-PCR)
Reverse transcription of RNA and PCR amplification of cDNA was carried out 
using RNA PCR Kit (GeneAmp RNA PCR kit, Perkin-Elmer Cetus, Norwalk, 
Connecticut, USA) following the manufacturer’s instructions, modified to 
facilitate treatment of samples with DNase 1.
The Dnase 1 treatment was carried out in the same reaction mix prior to addition 
of the reverse transcriptase.
The oligonucleotide primers for rt-PCR amplification were synthesised on the 
Applied Biosystem DNA Synthesiser as described in section 2.2.2.3.
One microgramme of total RNA in 2pi of DEPC-treated water was mixed with
16.5 pi of reverse transcriptase master mix excluding reverse transcriptase [final 
concentrations in 20pl = 5 mM MgCl2 , IX PCR buffer (50 mM KC1, lOmM Tris- 
HC1, pH 8.3), 1 mM each dNTPs, 20 units of RNase inhibitor and 2.5pM random 
hexamers]
Contaminating DNA was removed by adding 0.4pl of 0.25 pg/ pi of RNase-ffee 
DNase 1 (USB) and incubating at 37°C for 30 minutes. The reaction was then 
stopped by heating to 95°C for 5 minutes and then cooled to room temperature. 
One microlitre of 50 U/pl of maloney murine leukaemia virus reverse 
transcriptase was then added and the rt-PCR procedure followed according to the 
manufacturer’s instructions, including one round of reverse transcription (42°C
for 15 minutes, 99°C for 5 minutes and soaked at 5°C for 5 minutes) in a total
volume of 20 pi, followed by addition of 80pl of PCR master mix containing Taq 
polymerase and primers specific for the genes of interest (MUCI, K19 or CD44) 
(final concentration in 100 pi = 2mM MgC12, IX PCR buffer, 2.5 units of
AmpliTaq DNA polymerase, and 100 ng of each upstream and downstream 
specific primers).
The PCR reaction was carried out in a Perkin-Elmer Cetus 480 DNA thermal 
cycler; the PCR conditions for each set of primers are given below. A preceding 
single cycle was the same for all sets of primers and consisted of denaturing cycle 
at 93°C for 5 min, primer annealing at 55-60°C for 5 min and polymerization at
72°C for 15 min.
The PCR conditions for MUCI were 30 cycles: 93°C for 1 min, 60°C for 1 min 
and 72°C for 5 min and a final extension cycle at 72°C for 15 min. The MUCI 
primers produced a 288 bp PCR product.
For CK19, the PCR conditions were, 40 cycles of a single round were carried out 
as described above to yield a 1097 bp PCR product. Where two rounds of PCR 
were performed, nested primers were used as described by Datta et al. (1994).
For CD44, the PCR conditions were, a first round of 20 cycles (using the primers 
for the standard form of CD44 which produced a fragment of 486 bp) and a 
second round of 30 cycles where 1-2 pi of first round PCR product was used as a 
template in a lOOpl reaction containing either Exon 8-11 or Exon 12-14 primers. 
For all samples, the quality of RNA was routinely checked by running the 
standard form of CD44(S) as an internal control. Positive controls were RNA 
extracted from MCF-7 cell lines and ‘negative controls’ contained all components 
of the rt-PCR reaction but no target RNA template. ‘Positive controls’ of RNA 
extracted from MCF-7 and/or MDA cell lines were routinely included.
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2.3.4 Primer sequences for rt-PCR
Prepared as previously described in 2.22.3 
MUCI:
M U C 1 - 5 '  primer 5 ’ CGTCGTGGACATTGATGGTACC - 3 ’
M U C 1 - 3 '  primer 5 ’ GGTACCTCCTCTCACCTCCTCCAA - 3 ’
CK19:
CK19 - 5' primer 5 ’- TTATTGGCAGGTCAGGAGAAGAGCC -3 ’
C K 19 - 3' primer 5 AGCTAACCATGCAGAACCTCAACGACCGC -3 ’
CD44:
CD44 (S) - 5’ primer 
CD44 (S) - 3’ primer 
CD44 (Exon 8-11) - 5' primer 
CD44 (Exon 8-11) - 3' primer 
CD44 (Exon 12-14) - 5' primer 
CD44 (Exon 12-14) - 3' primer
5 ’ AGTCACAGACCTGCCCAATGCCTTTG - 3 ’
5 ’ CACCTTCTTGACTCCCATGTGAGTGT - 3 
5 ’ CTTGGATCCAACCACACCACGGGCTTTTGACCACA -3 ’ 
5’ CTTGGATCCTTCTTCCTGCTTGATGACCTCGTCCC -3 ’ 
5 ’ ATATGGACTCCAGTCATAGTACAACGCTTCAGC -3 ’
5 ’ CTGATAAGGAACGATTGACATTAGAGTTGGAAT -3 ’
2.3.5. Seeding experiments
To assay the sensitivity of the technique, seeding experiments were carried out by 
adding varying concentrations of MCF-7 cells (0 -106 cells) to 10 mis of normal
blood. RNA was then extracted and quantified as described in section 2.2.3.2 and 
rt-PCR for MUCI and CK19 performed as described in section 2.2.3.3.
2.4 RNA Fingerprinting
RNA Fingerprinting reactions were carried out using Delta™ RNA 
Fingerprinting Kit (Clontech Laboratories, Inc., CA94303-4607, USA) following 
the manufacturer’s instructions.
2.5 Molecular cloning
Molecular cloning reactions were carried out using TA Cloning Kit and INV a  F’
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One Shot™ Kit (Invitrogen Corporation, San Diego, USA) following the 
manufacturer’s instructions.
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3. Results
For all reactions PCR optimization was performed under the conditions 
described in section 2.2.3. Those initial steps involved adjusting the 
annealing temperature and all the PCR components to determine if the 
conditions for amplifications were optimal and to eliminate the possibility 
of non-specific amplification by the primers. This step was time 
consuming because of the many variables involved in different 
experiments.
There was no detectable difference in PCR amplification products in 
samples collected in bottles containing Lithium heparin or EDTA 
demonstrating no significant inhibitory effect of heparin anticoagulant on 
PCR (Figure 6).
The seeding experiments demonstrated a decreasing signal from MUCI 
mRNA corresponding to a decreasing number of seeded tumour cells, 
reflecting an apparent sensitivity of 1 tumour cell per ml of blood. 
However, the unseeded blood sample in lane 1 showed a faint band, 
casting doubt on the specificity expression of MUCI mRNA (figure 1A). 
Further samples of normal peripheral blood showed variable expression of 
MUCI mRNA in 4 of 6 volunteers (figure IB). A further experiment was 
performed using the standard form of CD44 (CD44s) mRNA as internal 
control. Similar background expression was demonstrated in peripheral 
blood samples from healthy human volunteers (figure 1C). This variation 
in expression was not due to degradation of RNA in some specimens since 
CD44s was equally represented in each (figure ID). In total, peripheral 
blood from 21 of 23 volunteers showed positive bands when assayed for 
MUCI mRNA.
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The results of the assay for variants of CD44 in peripheral blood from 10 
healthy volunteers is depicted in figure 2. The metastasis-associated 
variant (Exons 8-11) mRNA is present in 4 of 10 samples.
In contrast, CK19 mRNA was not detected in 48 samples of normal 
peripheral blood (figure 3 and 4). However, under the experimental 
conditions used, the seeding experiments demonstrated that it was
impossible to detect tumour cells at concentrations less than 104 cells per
10 ml of blood i.e. one tumour cell per 104 white cells (figure 5). This 
failure of detection did not appear to be due to degradation of RNA since 
CD44s mRNA was detected in all these samples by rt-PCR (figures 3A 
and 5A). In order to increase the sensitivity of detection, we attempted to 
use nested primers as described by Datta et al (1994), but abandoned this 
in light of frequency of detection of CK19 mRNA in blood from healthy 
volunteers.
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Figure 1
Figure 1. Sensitivity and specificity of MUC1 mRNA
A: Autoradiographic detection of MUC1 mRNA in blood samples from a 
healthy subject mixed with serial dilutions of MCF-7 cells after 30 cycles 
of PCR amplification and hybridization with 32p-labelled MUC1 
oligonucleotide.
Lanes 1 to 6 = 0, 10, 102, 103, 104 and 105 MCF-7 cells/10 ml of blood
respectively; lane 7 = MCF-7 mRNA.
B: Autoradiograph of Southern blot showing hybridization of 32p-labelled 
MUC1 oligonucleotide to 30 cycles PCR product. It demonstrates 288 bp 
DNA in the MCF7 mRNA (lane 8) and in 4 out of 6 normal peripheral 
blood samples (lanes 2,5,6 and7).
Lane 1= “No”RT control.
C: Ethidium bromide-stained agarose gel of rt-PCR product from MUC1 
mRNA in 5 other normal bloods (lanes 2-6). Lane 1= “No” RT control, 
Lane 7 = MCF-7 mRNA.
D: Ethidium bromide-stained agarose gel of rt-PCR product for CD44s 
mRNA as internal control for the integrity of RNA of all samples of 
normal blood and MCF-7 mRNA in Fig 1C.
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Figure 2
Figure 2. Detection of CD44 (Exon 8-11) mRNA in normal blood
Ethidium bromide-stained agarose gel of rt-PCR product for CD44 mRNA 
showing expression of exon 8-11 in 4 out of 10 samples of peripheral 
blood from healthy volunteers (lanes 4,5,8 and 10). The rt-PCR product of 
exon 12-14 is used here as internal control.
Lane 11= MCF-7 mRNA and Lane 12 = “No”RT control.
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Figure 3
Figure 3. Specificity of CK19 mRNA
A: Ethidium bromide-stained agarose gel showing 486 bp bands of CD44s 
as internal control for 5 blood samples (lanes 2-6) and MCF-7 cells (lane 
T).
B: Ethidium bromide-stained agarose gel of rt-PCR product from CK19 
mRNA. Lanes 7 = MCF-7 mRNA. Lanes 2-6 = Normal blood samples 
showing no visible bands.
C: Southern blot showing hybridization of 32p-labelled CK19 
oligonucleotide to 40 cycles PCR product. This shows a 1069 bp band in 
the MCF-7 cells and confirms its absence in 5 normal blood samples.
Lane 1 = “No” RT control.
CD44s
Figure 4
Figure 4. Specificity of CK19 mRNA
A: Ethidium bromide-stained agarose gel of rt-PCR product from CK19 
mRNA. Lane 13 = MCF-7 mRNA. Lanes 2-12 = Normal blood samples 
showing no visible bands. Lane 1= “No” RT control.
B: Ethidium bromide-stained agarose gel of rt-PCR product from CK19 
mRNA. in 15 other normal bloods (lanes 2-16). Lane 1= “No” RT control, 
Lane 17 = MCF-7 mRNA.
C: Ethidium bromide-stained agarose gel of rt-PCR product from CK19 
mRNA. in 17 other normal bloods (lanes 2-18). Lane 1= “No” RT control, 
Lane 20 = MCF-7 mRNA.
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Figure 5. Sensitivity of CK19 mRNA
A: Ethidium bromide-stained agarose gel showing bands of CD44s as 
internal control for the integrity of RNA.
B: rt-PCR detection of CK19 mRNA in blood samples from a healthy 
subject mixed with serial dilutions of MCF-7 cells detected on ethidium 
bromide-stained agarose gel after 40 cycles of PCR amplification.
C: Southern blot and hybridization of 32p-labelled CK19 oligonucleotide 
to 40 cycles PCR product of Fig-4B.
Lanel= “No” RT control; lanes 2 to 8 = 0, 10, 102, 103, 104, 105 and 106 
MCF-7 cells/10 ml of blood, respectively.
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Figure 6
Figure 6. Heparin vs EDTA
A: Ethidium bromide-stained agarose gel of rt-PCR product from MUC1 
mRNA in the same sample of normal blood (lanes 1 = sample collected in 
bottle containing Lithium heparin-2 = sample collected in bottle 
containing Potassium EDTA). Lane M= 100 bp ladder marker.
B: Ethidium bromide-stained agarose gel of rt-PCR product for CD44s 
mRNA (lanes 1-6). Lanes 1-3 = samples collected from three normal 
volunteers in bottles containing Lithium heparin. Lanes 4-6 = 
corresponding sample collected in bottle containing Potassium EDTA .
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RNA Fingerprinting
Differential display reactions were performed to compare the pattern of expression of 
breast carcinoma with that of normal blood. For these reactions multiple tumour and 
blood samples were used. RNA was prepared from ten malignant breast tumours and 
ten blood samples from healthy female volunteers. RNA was extracted as previously 
described in section 2.2.3. RNase-free DNase was used to remove contaminating 
DNA as this may interfere with the identification of differentially expressed bands 
(Liang et al., 1995). The initial fingerprinting experiments demonstrated that all 
contaminating DNA had been removed .
A 1 pg aliquot of each tumour RNA was taken and combined to give the tumour mix. 
The same was done for the normal blood samples. Each RNA mix was reverse- 
transcribed into cDNA.
The generation of fingerprints is sensitive to template quality and small changes in 
template concentration. It is therefore necessary to control for the possibility that an 
observed difference between two RNA samples is due to slight differences in RNA 
quality or concentration. Repeated fingerprinting at only one concentration does not 
control for these effects. The simplest way to ensure the authenticity of a differentially 
amplified product is to fingerprint a titration of the RNA. Only products that occur at 
two or more concentrations in one sample and not at all in the other sample should to 
be considered (McClelland et al., 1994). Therefore each cDNA was diluted to give the 
"A" dilution (1 in 10) and the "B" dilution (1 in 40) and fingerprinted.
A total of 30 anchored and arbitrary primer combinations were used (Tl-9 and P4-6). 
The number and intensity of the bands in a fingerprint depended on the primer 
combination used. A small number produced fingerprints which were too faint to be of 
use. Using this limited primer combination, a total 18 of such differentially expressed
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bands were recovered for further characterization. These bands ranged in size from 
approximately 300-700 bp.
As shown in figure 7 many PCR products were found to be expressed in both breast 
cancer and normal blood. Whereas other products were expressed in breast cancer 
only.
These differentially expressed bands were cut out from the dried down gel, 
reamplified and cloned into the TA cloning vector pCRII (Invitrogen).
Reamplification of PCR products under the conditions described in section 2.3 has 
confirmed the size of the differentially expressed bands (Figure 8).
Before ligation into a vector, the reamplified bands were further treated with 
phenol/chloroform and figure 9.B demonstrate the 450 bp band after 
phenol/chloroform extraction.
Plasmid minipreps of 2 to 4 clones from each band were digested with EcoRX and 
run on an agarose gel to determine the size of the insert. Figure 10 shows the 450 bp 
fragment after digestion of the insert of nine clones with EcoRX.
A selection of the clones were partially sequenced (seql-18) and the sequences 
compared against the GenBank/EMBL nucleic acid data bases .
The results of sequencing of multiple clones produced from one band have shown that 
the inserts were often heterogenous with respect to size, but also the sequence of the 
clones with apparently the same size insert were different. This observation has been 
subsequently confirmed with all other bands as they have been processed further (data 
not shown).
When tested as a potential marker, the 450 bp band was found to be expressed in 4 
normal blood samples as figure 11 shows. Similar experiments showed all of 18
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differentially expressed bands studied, demonstrated variable degree of expression 
normal blood rendering them non-specific.
Figure 7
Figure 7. PCR Fingerprinting reactions
Autoradiograph of polyacrylamide gel electrophoresis showing differential 
display of mRNA from normal blood versus breast carcinoma using three 
different primer combinations.
Lane cDNA sample Primers
1 1A P5T7
2 2A P5T7
3 IB P5T7
4 2B P5T7
5 1A P5T8
6 2A P5T8
7 IB P5T8
8 2B P5T8
9 1A P5T9
10 2A P5T9
11 IB P5T9
12 2B P5T9
RNA from breast carcinoma were compared to RNA o f  normal blood, 
1 A: dilution A  o f  cD N A  made from breast cancer RNA  
IB: dilution B o f  cDNA made from normal blood RNA  
2A: dilution A o f  cDNA made from breast cancer RNA  
2B: dilution B o f  cDNA made from normal blood RNA
Lane 8 shows 4 differentially expressed band fragments (arrows) which were excised for 
further analysis,
Band 1 ~  750bp 
Band 2 ~  500bp 
Band 3 ~  450bp  
Band 4 ~  390bp
1 2 3 4 5 6 7 8 9 10 11 12
Z
ii
Figure 8
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Figure 8. Reamplification of differentially expressed bands
2% Ethidium bromide gel after 20 cycles of PCR amplification of eluted bands 
with the primer sets used in the original fingerprinting reaction. Lane M = 100 bp 
ladder marker. Lane 1= 800 bp band. Lane 2 = 450 bp band. Lanes 3-8 = other 5 
bands between 400- 600 bp. Lane 9 = “No” RT control.
M 1 2 3 4 5 6 7 8 9 10
Figure 9
Figure 9. Reamplification of differentially expressed bands
A: 2% Ethidium bromide gel after 20 cycles of PCR amplification of eluted bands 
Lane M = 100 bp ladder marker. Lane 1= 800 bp band. Lane 2 = 450 bp band.
B: Lane 2 = DNA amplification product after phenol/chloroform extraction for 
the 450 bp band shown in A, which is now ready for ligation into pCR™II.
M. 4 5 0  b p 4 5 0  bp
Figure 10
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Figure 10. Digestion of inserts
2% Ethidium bromide-stained agarose gel
Lane M = 100 bp ladder marker, lanes 1-9 = digestion of the inserts in from 9 
white colonies showing the 450 bp bands (bottom arrow) and the rest of plasmid 
(top arrow), lane 10 = a blue colony which does not contain the 450 bp insert.
M 1 2  3 4 5 6 7 8 9 10
Figure 11
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Figure 11. Specificity of the 450 bp differentially expressed band
2%Ethidium bromide-stained agarose gel of rt-PCR product from (450 bp 
band) mRNA. Lane 1 = 100 bp ladder marker. Lane 8 = “No” RT control. 
Lane 9 = MCF-7 mRNA 1, Lanes 1-7 = Normal blood samples showing no 
visible bands in lanes 2,4 and 6.
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4. Discussion
The previously reported results of a study by Brown et al. (1995) 
concluded that the DF3 (MUC1) antigen may be used as a specific marker 
for detecting circulating tumour cells in patients undergoing surgery for 
breast cancer. Under similar experimental conditions we have 
demonstrated almost ubiquitous background expression of MUC1 in the 
peripheral blood of 21 of 23 healthy female volunteers. In support of these 
findings, Hoon et al. (1995) also detected MUC1 expression in 7 of 8 
normal donor peripheral blood leucocytes and four normal lymph nodes. 
The specific occurrence of variant CD44 mRNA in tumour cells has been 
described by Matsumura et al. (1992). They reported that peripheral blood 
leucocytes expressed the standard form of CD44 without the splice 
variants. CD44 (Exon 8-11) is implicated in the metastasis of rat 
pancreatic tumour cells (Gunthert et al., 1991; Hofmann et al., 1991) and 
the sequences spliced into a CD44 variant believed to be expressed in 
colonic tumour and breast cancer (Delatorre et al., 1995). Our results also 
raise serious doubts about the value of using CD44 (Exons 8-11) to detect 
circulating tumour cells because of the frequency with which it is found in 
normal peripheral blood. It is not known whether expression of these two 
markers in normal peripheral blood is due to low level of expression of 
genes in a proportion of peripheral blood cells, or due to presence of a few 
epithelial cells in the blood of some individuals.
CK19 was not expressed in the peripheral blood of healthy volunteers 
and in theory could be a specific epithelial marker. However, the 
sensitivity of detection of CK19 in a single round of amplification was 
limited to greater than 104 cells per 10 ml of blood. Because of the
frequency with which CK19 mRNA was detected in normal blood after 
two amplification rounds, we abandoned using the nested primers 
described by Datta et al. (1994) which were designed to increase 
sensitivity. We also found increasing the number of cycles in a single 
amplification round above 40 cycles enhanced sensitivity but reduced 
specificity as previously reported by Schoenfield et al.(1994). Several 
reptitions produced the same results. The failure to detect lower 
concentrations of tumour cells did not appear due to degradation of RNA 
since undegraded CD44(S) mRNA was detected in these samples by rt- 
PCR.
Our studies clearly demonstrate that, while rt-PCR has the potential to 
detect minute quantities of a specific RNA sequence against a 
background of a vast excess of other RNA, there are dangers in assuming 
that the technique can be used to detect minute numbers of specific cells 
because of the well-established phenomenon of illegitimate transcription 
which results in very low levels but non-specific expression of irrelevant 
genes in many cell types (Chelly et al., 1989). Illegitimate transcription 
limits the usefulness of rt-PCR to detect another putative epithelial cell- 
specific mRNA (De Graaf et al., 1997). Nevertheless, we used CK19 
primers which were designed to preclude the amplification of the 
pseudogene sequence (Datta et al., 1994). We also routinely treated all 
RNA preparations with RNase-free DNase 1, and ran 'no-RT' controls 
with all reactions.
The data on CK19 in the literature are contradictory. Several authors have 
reported no transcription of CK19 mRNA in normal blood (Datta et al.,
1994; Traweek et al., 1993; Kruger et al., 1996) whilst transcription of 
CK19 mRNA in normal blood has been reported by Burchill et al., 1994 
and Krismann et al., 1995). Noguchi et al. (1996) reported no transcription 
of CK19 mRNA in lymph nodes, while transcription in lymph nodes was 
observed by Schoenfield et al., (1994).
It is clear that rt-PCR can be a highly sensitive and specific method of 
detecting minute quantities of a specific RNA. However, this study raises 
serious concern about the background expression detected in peripheral 
blood of healthy female volunteers.
The technique of immunobead-PCR may be a solution to the problem if 
combined with detection of an irrefutable genetic marker of a tumour such 
as K-ras mutations (Hardingham et al., 1993; 1995). It may be applicable 
in those tumours that carry the mutated gene. Such a specific mutation is 
as yet unknown in breast cancer.
The PCR is difficult to quantitate, nevertheless, serial dilutions can be 
performed by comparing the amplification over a range of RNA or DNA 
concentrations for a target gene with a control gene during the 
exponantial phase of amplification. As the level of gene expression and 
transcription rate between individuals vary according to the prevalence of 
the encoded protein, this semi-quantitative way may not provide distinct 
information regarding tumour cell number. It may also fail to give sound 
and accurate information despite the continued presence of tumour cells 
when transcription is momentarily down regulated due to the effect of 
chemotherapy. Further more, because of intermittent tumour cell
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shedding, blood samples may not contain the adequate number of 
circulating tumour cells.
Immunofluorescent detection using a multi-colour FACS technique are 
alternative approaches for detection of circulating tumour cells, but sample 
size is a limiting factor for the utilisation of immunofluorescent detection 
using a multi-colour FACS technique.
Further work is essential to identify a suitable epithelial marker that has 
the required specificity and sensitivity to be used reliably in the detection 
of circulating tumour cells from solid tumours and meticulous attention to 
methodology is required to overcome the technical problems with this 
method before its broader use in clinical practice can be recommended.
The primer combination used in the latter part of the work performed in 
the RNA fingerprinting is a representative sample of a total of 90 studied. 
One disadvantages of the differential display that a large number of bands 
are generated which do not represent differentially expressed mRNA. 
Potentially expressed clones may be made up of more than one cDNA 
species (Liang et al., 1995) and hence the resulting clones produced are 
heterogenous in nature. This necessitates a method for screening large 
numbers of clones quickly to determine which are differentially expressed 
before they can be characterized further.
Due to the restricted amounts of RNA that we obtained from the blood and 
tumour samples it was necessary to use another method to initially 
determine differential expression of those 18 bands and save the limited 
RNA for Northern blots for more promising bands. Upstream and down 
stream primers from the sequences of the differentially expressed bands
were used as potential markers to screen normal blood of healthy 
voulnteers. This is less than ideal. Nevertheless, the non-specificity of 
those 18 bands determined that they were not genuinely differentially 
expressed, and therefore were not characterized further.
For the differential display to be fully evaluated, the whole range of 
arbitrary and anchored primer combination must be used in a set up which 
has the necessary expertise and enough cDNA stocks for characterization 
of the differentially expressed bands.
Future work in RNA fingerprinting should encompass a more 
comprehensive study to utilise the potentials of the technique, with an 
extension of the approach to compare malignant breast tumours with 
benign tumours, normal breast epithelial cells in addition to normal blood. 
When a suitable epithelial marker has been identified, it should be tested 
in similar experiments described in this thesis, prior to use in clinical 
practice.
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MATERIALS
1 Cell lines, media and tissue culture supplies
MCF7 breast carcinoma cell lines were obtained from laboratory stocks.
Supplier: Beatson Institute Central Service
- sterile water
- sterile PBS
- sterile glassware and glass pipettes
Supplier: Costar, 1 Alewife Ctr, Cambridge, MA 02140, USA
- sterile disposable cell scrapers
Supplier: Fisons Europe Life Technologies Ltd., Paisley, U.K.
- dimethylsulphoxide (DMSO)
Supplier: Gibco Europe Life Technologies Ltd., Paisley, U.K.
- Foetal calf serum (FCS)
- 200mM glutamine
- lOOmM sodium pyruvate
- 7.5% (w/v) sodium bicarbonate
- 2.5% (w/v) trypsin
Supplier: A/S Nunc, Roskilde, Denmark 
-Tissue culture flasks
- Nunc tubes
Supplier: Worthington, New Jersey, USA 
-Trypsin
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2 Chemicals
Supplier: British Drud House Chemicals Ltd.,Poole, Dorset, U.K.
Unless otherwise stated, all chemicals used were obtained from BDH and were 
generally AnalaR Grade or better.
Supplier: Amersham International pic, Amersham, Bucks., U.K.
- [y-32 P] ATP ~ 5000Ci/mmol
- [a 35S ] dATP ~ 600Ci/mmol
Supplier: Bethesda Research Laboratory, Life Technologies, Inc., USA
- agarose, ultra pure electrophoresis grade
- LMP agarose, ultra pure electrophoresis grade
Supplier: Cinna/Biotecx Laboratories Inc., Houston, Texas, USA
- RNAzolB
Supplier: Difco laboratories, Detroit, Michigan, USA
- bactro-tryptone and agar
Supplier: Fison Scientific Equipment, Loughborough, U.K.
- acetic acid
- chlorophorm
- glycerol
Supplier: James Burrough Ltd., Witham, Essex, U.K.
- ethanol
Supplier: Koch-Light Ltd., Haverhill. Suffolk, U.K.
- isoamyl alcohol
Supplier: National Diagnostics, Manville, New Jersey, USA
- ecoscint A
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Supplier: Rathburn Chemicals Ltd., Wakeburn, U.K. 
- phenol
Supplier: Sigma Chemical Co., Ltd., Poole, Dor set, U.K.
- Ampicillin
- bromophenol blue
- bovine serum albumin (BSA) (fraction V)
- ethidium bromide
- methylene blue
- salmon sperm DNA 
-TMED
Supplier: Unipath Ltd., Basinstoke, Hants., U.K.
- PBS (Dulbecco A, tablet form)
3 Enzymes
Supplier: Nothumbria Biologicals Ltd., Cramlington, Northumberland, U.K.
- RNase A
- T4 polynucleotide kinase
Supplier: Promega, Southhampton, Hampshire, U.K.
- Taq DNA Polymerase + reaction buffer
Supplier: Sigma Chemical Co., Ltd.,Poole, Dorset, U.K.
- lysozyme
- Phenol: Chloroform
4 Kits
Supplier: Clontech Laboratories, Inc., CA94303-4607, USA
- Delta ™ RNA Fingerprinting Kit
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Supplier: Hybaid Limited, Middlesex, UK
- Hybaid Recovery ™ Plasmid Mini Prep Kit
Supplier: Invitrogen Corporation, San Diego, USA
- TA Cloning Kit
- INV a  F’ One Shot™ Kit
Supplier: Perkin Elmer Cetus, Norwalk, CT 06859, USA
- Gene Amp PCR reagent kit
Supplier: United States Biochemicals, Cleveland, Ohio, USA
- Sequenase version 2.0 kit
5 Markers
Supplier: Bethesda Laborotaries Research, Gibco Ltd, Paisley, U K
- <|)X174 RF DNA / Hind III fragment
- lOObp DNA ladder
6 Membranes, paper, TLC plates and X-ray film
Supplier: Amersham International pic, Amersham, Bucks., U.K.
- Hybond N+
Supplier: Camlab Ltd., Cambridge, U.K.
- Polygram TLC plates
Supplier: Eastman Kodak Co., Rochester, New York, USA
- X-ray film (XAR)
Supplier: Sartorius Ltd., Epsom, Surrey, U.K.
- nitrocellulose membranes
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7 Water
Distilled water for buffers and all general solutions were purified through a Millipore 
MilliRO 15 system. Water for procedures which required further purification was 
obtained from a Millipore MilliQ system at 18 MQ cm.
1.8 Blood
Normal blood, normal and malignant breast tissue were used to provide material for 
rt-PCR and RNA fingerprinting and were obtained by informed consent from 
volunteers and patients attending the Department of Surgery at the Western Infirmary- 
Glasgow.
9 Solutions
DEPC Treated Water (0.1%)
999 ml double distilled water 
lml DEPC 
Autoclave solution
Denhardt’s Solution (lOOx)
2% (w/v) BSA fraction V 
2% (w/v) Ficol™
2% (w/v) PVP
made up with DEPC treated water
DNA dye Mixture
30% v/v Glycerol
0.25% w/v Bromophenol blue
0.25% w/v Xylene cyanol
0.5M EDTA (pH 8)
186.1 g Na ethylenediamine tetraacetate.2H20
800 ml Water
Adjust pH to 8 with NaOH
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3M NaAc (pH 7)
408.1 g3NaAc.3H20  
800ml Water
Phosphate Buffered Saline (PBS)
0.8% NaCL 
0.115%Na2 HPO4 
0.02% KCL 
0.02% KH2P04
Prehybridisation buffer (100ml)
48ml Water
20ml 50x Denhardt’s solution
30ml 20x SSC
02ml sDNA (5mg/ml stock)
RPMI
800ml sterile distilled water 
26.6ml 7.5%NaHC03 
10ml lOOmMNa Pyruvate 
10ml 200mM L-Glutamine 
lml lMNaOH 
100ml Foetal Calf Serum 
100ml RPMI 1640 (lOx)
R.B.C. Lysis Buffer (lOx)
8.3% NH4 CL 
0.37g/l Na2 EDTA 
10.0g/l KHC03
10%SDS (pH 7.2)
lOOgSDS
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900ml Water
SSC (20x) pH 7
175.3 gNaCL 
88.2 g Na citrate 
800ml H20
Sequencing loading solution
950 pi deionized Formamide 
50 pi TBE buffer (20x)
0.1 mg Bromophenol blue 
0.1 mg Xylene cyanol
TBE(lx) pH8
89mM Tris borate 
89mM boric acid 
2.5mM EDTA
X-gal (5-bromo-4-chloro-3-indolyl-p-D-galactosidase) 
prepared in dimethyl formamide
APPENDIX 2: RNA Fingerprinting sequences
BAND l.S eq  (P5T7)
LENGTH: 452
1 TTGNTTACGG CCANTGGGCT TGTAATACTA CTCACTATAG GGCGAATTGG 
51 GCCCTCTAGA TGCATGCTCG AGCGGCCGCC AGTGTGATGG ATATCTGCAG  
101 AATTCGGCTT A T T A A C C C T C  A C T A A A G A T C  T C A C T G A A A A  ATAAAGTTTT  
151 TGAACAATTT CATGAAGGTT GGGTTGTCGA GATCATGAGT TCTGTCTCTA 
201 ATGACAACTC TGTGGGAAAT GGATAAACTC TGATAAACTC TATCGCACTG  
251 CACACAAATG TGAGGCTGGA AGGCAGTACG TAATTTATGA GGCCTTTTGT 
301 TGTAAAAATG AGAGTTGGCA GGATTCCGAG TAAATATCTT TTTTCCTAAG  
351 GGTGGAAGAT AGGACTTGGA GAGATCAATA TGTTGGTTGA CAGCATTCGA  
401 GAATGTTTGA TTTGAGCTTC AGCATCATAG GTGGGGAACA TGTNGCTTTA 
451 TC
1 vu'v\<ux1 P n m e i  . I l l  - 136
BAND 2.Seq (P5T8)
LENGTH: 455
1 NCCTTAGNTG NNTAAGGCCA CTGGNCCCGT TATACTTTTC ACTATAGGGC  
51 GAATTGGGCC CTCTAGATGC ATGCTCGAGC GGCCGCCAGT GTGATGGATA  
101 TCTGCAGAAT TCGGCTTA I T  A A C C C T C  A C T  A A A G A T C T G A  CTGCAGAAAA  
151 CTGGTCAATA ATTTATCCTA GGGTAGAAAA AGCTAAGGAA CT AN A AAAAG  
201 AAAATATAAC ATNTACAGAT GTGTNGGTCA CTANTCTNGT CCACTTCATT 
251 GTGGATNCTG ANGCACCTCT GAGCCCGTGT AAAGGCCACG GGATCAGTGA  
301 TGAAGANAAT CNATTTCGTC TCAGCTGCCA CGTGCCCTGC AGAGGTGGCC  
351 AGCATTAGAA GGTAACGCAT ATGGTATACA AATCCTCTCA TCTCCTTCNG 
401 TCAGATCTTT AGTGAGGGTT GGTAAGCCGA ACTCCAGCCA CTGGCGGGCG 
451 NTACC
Korn  ai d Prime] '  : 1 1 8 -  143
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BAND 3.Seq (P5T8)
LENGTH: 449
1 NG NNANNNCT TAAGNNCCGT GACACTATTC ACTATAGGGC GAATTGGGCC 
51 CTCTAGATGC ATGCTCGAGC GGCCGCCAGT GTGATGGATA TCTGCAGAAT 
101 TCGGCTTATT A A C C C T C A C T  A A A G A  I 'CTGA CTGCCACTGT TGGCTTTATT 
151 GCACTAGCCA GTATCACAGA GAGTTCCACT AACAGCAGGG GGATGAAACT  
201 GTTGATGCTG TTATCAACAG AAATTGTCAA TTACCTGACA GCAGACACTA  
251 GGTGCTACTT GTTAGAGGCA AAAAAAAAG A TATCACTCAG CATAATAAGC  
301 CGAATTCCAG CACACTGGCG GGCCGTTACT AGTGGATCCG AGCTCGGTAC  
351 CAAGCTTGGC GTAATCATGG TCATAGCTGT TTCCTGTGTG AAATTGTTAT 
401 CCGCTCACAA TTCCACACAA CATACGAGCC GGAAGCATAA AGTGTAAAG  
f orwa rd  P r i m e r : 108 - 133
BAND 4.Seq (P5T8)
LENGTH: 457
1 NCNNGTNTAG ANNCAGCCCT GACCCGTAAA ACTATTCACN ANAGGGCGAA  
51 TCGGGGCCCT CTAAATGCAT GCTCGAGCGG CCGCCAGTGT GATGGATATC 
101 TGCAGAATTC GGCTTA 1TAA C C C T C A C T A A  A G A F C T G A C d  GGATGGGGTT 
151 ACCGGGTTAT CGCTTTGCAG TATCCAGTTN ATCGGGACCA TCTCGAGNNN  
201 NGTGATGGAT CCAGAAAACT TNTAGACCAT TTACAATTGG ATAAAGTTCA  
251 TCTTTTTGGC GCTTCTTTGG GAGGCTTTTT GGCCCAGAAA TTTGCTGAAT 
301 ACACTCACAA ATCTCCTAGA GTCCATTCCC TAATCCNTCT GCAATTCCCT 
351 CAGTGACACC TCTATCTTCA ACCAAACTTG GAACTGCNAA CAGGATTAAA  
401 CCTCCATTTC AGCTAATCAT GGGAACAATT TAAGTCCCCT CCCGATTATN  
451 ACTGGTC 
l o rwa rd  Pr imer  : 116 - 141
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BAND 5.Seq (P5T8)
LENGTH: 449
1 CGNCTANCGT TAATGGCTTG TGACACGACT CACTATAGGG CGAATTGGGC  
51 CCTCTAGATG CATGCTCGAG CGGCCGCCAG TGTGATGGAT ATCTGCAGAA  
101 TTCGGCTTAT TAACCCTCAC T A A A G A T C T G  ACTGAAGGCA AGCATAATTT 
151 AGAGGAAAAG G CAAAAAAAA AGATATCACT CAGCTAATGA GTCCGAATTC 
201 CAGCACACTG GCGGCCGTTA CTAGTGGATC CGAGCTCGGT ACCAAGCTTG  
251 GCGTAATCAT GGTCATAGCT GTTTCCTGTG TGAAATTGTT ATCCGCTCAC 
301 AATTCCACAC AACATACGAG CCGGAAGCAT AAAGTGTAAA GCCTGGGGTG 
351 CCTAATGAGT GAGCTAACTC ACATTAATTG CGTTGCGCTC ACTGCCCGCT 
401 TTCCAGTCGG GAAACTGTCG TGCCAGCTGC ATTAATGAAT CGGCCAACG  
l o r w a r d  P t  i m e r  : 1 0 4  -  1 3 4
BAND 6.Seq (P5T8)
LENGTH: 450
1 TCTTNGNCCT GCCGGCCAGT GGAATTGTAA TACGACTCAC TATAGGGCGA  
51 ATTGGGCCCT CTAGATGCAT GCTCGAGCGG CCGCCAGTGT GATGGATATC  
101 TGCAGAATTC GGCTTA H  A  A  C C C T C  A C T A A  A G A T C T G A C T  GGAGCAGCAA  
151 AAAAAAAG AT ATCACTCAGC ATAAAAGCCG AATTCCAGCA CACTGGCGGC 
201 CGTTACTAGT GGATCCGAGC TCGGTACCAA GCTTGGCGTA ATCATGGTCA  
251 TAGCTGTTTC CTGTGTGAAA TTGTTATCCG CTCACAATTC CACACAACAT  
301 ACGAGCCGGA AGCATAAAGT GTAAAGCCTG GGGTGCCTAA TGAGTGAGCT 
351 AACTCACATT AATTGCGTTG CGCTCACTGC CCGCTTTCCA GTCGGGAAAC  
401 TGTCGTGCCA CCTGCATTAA TGAATCNGCC ACCCCCGGGA AAAGCGGTTG  
F o r w a r d  P r i m e r : 1  1 6  -  1 4 1
101
BAND 7.Seq (P5T9)
LENGTH: 452
1 NCGTATNACG CCAGTGGGCT TGTAATACGA CTCACTATAG GGCGAATTGG  
51 GCCCTCTAGA TGCATGCTCG AGCGGCCGCC AGTGTGATGG ATATCTGCAG  
101 AATTCGGCTT ATTAACCCTC ACTAAAGATC TGACTGATGT GATCTTATTT 
151 GGACAAAGAA GTGTTGTTGG AAATATCAGT CATGTGAATT AATTAACAAT  
201 TTCTTCCTTC CTAGCGAGAG TAAGACCATG GAGTAGAGCA GATATATTAG  
251 TCCATTCCAT GTGGAAATCC GGCCTGTAGT TGTATATTCG TATAGCTATA  
301 TGTTGGTAGG ATGGACCTAC ATGGTTTAAT GAAAGTGGAA GGAAAATCTA  
351 TTTTCAGTCA GATCTTTAGT GAGGGTTAAT AAGCCCGAAT TCCAGCACAC  
401 TGGCGGGCCG TTACTAGTGG ATCCGAGCTC GGTACCAAGC TTGGCGTTAT 
451 CA
Forward Prim er: 111 - i 36
BAND 8.Seq (P6T7)
LENGTH: 455 Mon,
1 NTNCNTNAGA NNAAGCCCTG NNCCGTAAAA CTATTCACNA NAGGGCGAAT  
51 CGGGCCCTCT AAATGCATGC TCGAGCGGCC GCCAGTGTGA TGGATATCTG  
101 CAGAATTCGG CTTATTAACC CTCACTAAAT GCTGGGTGTG GTGGCGCACA 
151 TCTGTAGTCC CTGCTACTGG AGAGGCTGAG GTGGGAGGAC TGCNNGAGCC  
201 TGAGGCTGCA GACAGCCATG ATCATGCCAC AGCTCTGGCA TGGGTGACAG  
251 AAAGAGACCC NATCTCAAAA A A AA AAAAAA ACAACCAGGT GTGCCGGATG  
301 CAGTGGTGCA TGCATGTAGT CCCAGCTACT TGGCTGAGGC AGGGACCATC  
351 ACCCGAGCCT CAGGAATTCC AAGCCGCTTT AAGCTANGAT GCACCCATGC 
401 CCCNGTGACT AAACCAANAC CCTTNCNCCN N A A A A A A A N A  ANNNCCCCCC  
451 CCCTC
Forward Prim er: 114 - 138
102
BAND 9.Seq (P5T3)
LENGTH: 451
1 GTCTTNAGCC TAGTGGCATG TTATACGACT CACTATAGGG CGAATAGGGC  
51 CCTCTAGATG CATGCTCGAG CGGCCGCCAG TGTGATGGAT ATCTGCAGAA  
101 CTCGGCTATT A A C C C T C A C  T A A A T G C T G G  GTGTNAAAAN CNACCGNACT  
151 CGTGAATTAT GTNCTNNANT NTACAATAGC GGATNCTAGT ACTANTATAT  
201 NTGANTTGAA TNCATTCCCT GAATCAGANG TACCAACGAG GTCAGAGTGT 
251 TNGTGTNCAN TCGGGANGCT TCGTGTCTCN CTATACCNCA TTTANATCTG  
301 ANNANTGTTA CTNATAGTGA TCAATGGGAA GGTNAGTTTA CCCCCCCGCT 
351 ATACTTGCCG NAACNANGTC ACANGTCNCC CGANCTNACC NCAAGCACNG  
401 ATGCTACCAC AACCCTTTAC GNGANNAACA TANCCTTCNC CATCCTCTGA 
451 CG 
F o r w a r d  P r i m e r  : 1 0 7  -  1 3 3
BAND lO.Seq (P4T3)
LENGTH: 459
1 GTGCTGNCTA AAAGCCANTG GNCCNGTAAA AACTTTTTCA CTATAGGGCG  
51 AATTGGGCCC TCTAGATGCA TGCTCGAGCG GCCGCCAGTG TGATGGATAT  
101 CTGCAGAATT CGGCTTAT 1 A  A C C C T C A C T A  A A T G C T G G T A  GGGATGTAAA  
151 TTAATTCAAC CACTATGGAA AGCTGTTTGG AGATTTCTCT AAGANCGGAA  
201 AACAGACCTA CCAACTGACC CAGCAATCCT ATTGATGGGT ATATACCCAA  
251 AAGAAAAG AA ATGATTCTAC CAAAAAGACA CATGCACTCT ATATTCATCA  
301 CAGTGCTATT CACAATAGCA AAAACATGGA CTAAACCTAA GTGCCCATCC 
351 ACAGTAGACT GGATGAAGAA AATATGGTAC ATACACTTCA TNGAATACTA  
401 TGCANCCCNT AAAAAGAATT AANTCATGTC CCTTGCNNCC ACCCCAATNC  
451 CNGGTGGAT 
! o r w a r d  P r i m e r  : 1 1 7  -  1 4 1
103
BAND ll.Seq (P4T3)
LENGTH: 444
1 TGTGGCNTTG ACGGCCAGTG AATTGTAATA CGACTCACTA TAGGGCGAAT 
51 TGGGCCCTCT AGATGCATGC TCGAGCGGCC GCCAGTGTGA TGGATATCTG  
101 CAGAATTCGG CTTATTAACC C T C A C T A A A T  G C T G G T A G G A  AGGTNAAANG  
151 GTGTAACNGC TGTGAATAAA AGTCTGTTGC TTCNNCTNAA AGCNAACNCN  
201 CCAGNGCCAC TCCCGCGGAN NTNGCAGTAC AATTGAAAAG GTTCTCANAC  
251 ACTTGTATGC CACTATTCAC TNCGGAAATA TNAGGCAAAN GGTGGACACA  
301 ATCCACGTAT CTTCCAACAG ATGAATGGAN ANACAATATG TGGTCTATAA  
351 ATACAACANT NCGTAATTCA GTAATAACAA GNAGTATGTG CTNCACTATG  
401 ATGAACCTTG AAANCCTCTA NTACCCACCT ACCGAAATTT TGAN  
I o r w a r d  P r i m e r  : 1 1 3 -  1 3 8
BAND 12.Seq (P4T4)
LENGTH: 450
1 NTGCTTNACG GCTAGTGGNC CTGTAATACT ACTCACTATA GGGCGAATTG 
51 GGCCCTCTAG ATGCATGCTC GAGCGGCCGC CAGTGTGATG GATATCTGCA  
101 GAATTCGGCT T A T T A A G C C T  C A C T A A A T G C  I G G T A G G A G G  TTATCCNATT 
151 ANCGANGGTA CC AC ATAT AG GTGCANGGTG CCTGTCATTC ACTGTNTTAT 
201 CTGGTNTANA TCGGNCTAAN NCTGGGGGAA GCTATNCTCT TTCAGTGGAT 
251 AATAAAATTG GTATCTCAAT CGTGAAACAT NTCANNGGTG TGTGAAGAAA  
301 AANCANCCNA TCTGTGGGTG TTGANATCTN GACCNTACTG TGTANGTTAC  
351 GTGCCTNTGT GGATGTGCAC TACCAGCATT TAGTGANGGT TAANAANCCG  
401 AATTCCACCA CACTGGCGGG CCGTTACTNN TGGATCCNAG CTCGGTACCT 
l o r w a r d  P r i m e r  : 1 1 2  -  1 3 7
104
BAND 13.Seq (P4T4)
LENGTH: 446
1 TGNTGNNTTA AGGCCAGTGG GCCTGTAATA CGACTCACTA TAGGGCGAAT  
51 TGGGCCCTCT AGATGCATGC TCGAGCGGCC GCCAGTGTGA TGGATATCTG  
101 CAGAATTCGG CTTATTAACC CTCACTAAAT GCTGGTAGNN CCACCGACNG  
151 NATCNTTCNC NAAAGACCTG CTTATCTACC ATNAAGATAN NTTCCTANCC  
201 GGCTCTGANC CTCAATCTCN CTGTGTGCCT GCATCTGNTT CNGNNCTGAA  
251 TATNCCTCTA CGGTGGANGG ANACATANGN NCTGGAGNTG TGCACNGATC  
301 CTCTTCGACT GGGCCTGGNT GGNGGTGTNT AAAGGCNAGG TNATACTTTC  
351 CCCCCCNTCN NGCATNTACT CCCACTTTCT CCTGAACTAN GGCCACCTAC 
401 TNANGGTGAA GGTTCNGAAT CCGAATTCCC TGGCNGNNGN GGCTGN  
I o r w a r d  P r i m e r  : 1 1 3  -  1 3 8
BAND 14.Seq (P4T4)
LENGTH: 450
1 GTNNGNCTTA GNCTTAGTGG GCCTGTAATA CGACTCACTA TAGGGCGAAT 
51 TGGGCCCTCT AGATGCATGC TCGAGCGGCC GCCAGTGTGA TGGATATCTG  
101 CAGAATTCGG CTTATTAACC CTCACTAAAT GCTGGTAGNG TACATATGCT  
151 GTCCCCTACC CCCCANGTGC NANAAG NAAG  CAGATGCTAT NTATNGGGGT  
201 TTNCTCACAN NGTNAGANGA CATTNGCCAG NGTCAATTGT NATTGACTGN  
251 NGCTATCNAG TAANTCCAAN GGAAACAGGT NTTTATGCCA CATTAANNTT  
301 NCNGAAACCA CCCATGCNNN GANNAGTTGC TACAGGTTAT GGGANAANAG  
351 AGTGCTGACA CCACTCGGTA TANGTTTACC ATGGAACTGT AATNACACTT  
401 TGTACTCTCA NAATCNNGTG C AC ATT AG AC TTCCTGTTTA TCTGTGATAN  
F o r w a r d  P r i m e r  : 1 1 4  -  1 3 8
105
BAND 15.Seq (P5T3)
LENGTH: 486
1 TGTGNTGNCT TAAGGCCAGT GGGCCTGTAA TACGACTCAC TATAGGGCGA  
51 ATTGGGCCCT CTAGATGCAT GCTCGAGCGG CCGCCAGTGT GATGGATATC  
101 TGCAGAATTC GGCTTATTAA C C C T C A C T A A  A G A T C T G A C T  GANNTCNNAA  
151 ATNANNCCTT AGGAGGTTGG ACNGCTCGGG CCCTNGTGTG A G NNAANNAN  
201 CCCTTNAGNA TGCCTTNTGG ACNNTACGGT GTCACNNTCA GACCATNGAC  
251 AGNGGGTNAN TCCCACATCT GTCNGTCTNA GAGGACTTGT CCNAACGCAC  
301 TTCAATANTC GTGGTTCTGN ACACAAAAGA TTTTGNTCAT NGAGAAAGCA  
351 GCTANGTTTA AGGTACCTAN CACATCGNAG GAAACGATGG CTNCNCACCC  
401 CCCNCCNATG NCCAGGNATT ANCCCTGTAT NGACTGGANC NCTTTCAAGG  
451 GCANGGANGA TCNTCCGCTG TNGGTGTCNN GTNCTT 
I o r w a r d  P r i m e r  : 1 1 6 -  1 4 1
B A N D  16.Seq (P6T3)
LENGTH: 452
1 GNCTTNAGCC TAGTGGCNTG TAATACGACT CACTATAGGG CGAATTGGGC 
51 CCTCTAGATG CATGCTCGAG CGGCCGCCAG TGTGATGGAT ATCTGCAGAA  
101 TTCGGCTTA I TAACCCTCAC IAAAIGCTGG G 1 GTNAAAAN CNACCGNACT 
151 CGTGAATTAT GTNCTNNANT NTACAATAGC GGATNCTAGT ACTANTATAT  
201 NTGANTTGAA TNCCTTCCCT GAATCAGANG TACCAACGAG GTCAGAGTGT 
251 TNGTGTNCAN TCGGGANGCA TCGTGTGTCN CTATACCNCA TTTANATCTG  
301 ANNANTGTTA CTNATNGTGA TCAATGGGAA GGTNAGTTTA CCCCCCCGCT 
351 ANACTTGCCG NAACNANGTC ACANGTCNCC CGANCTNACC NCAAGCACNG  
401 ATGCTACCAC AACCCTTTAC GNGANNAACN TANCCTTCNC CATCCTCTGT 
451 CN  
i o y w  aixi Primer : i 08 - i 33
106
BAND 17.Seq (P6T3)
LENGTH: 471
1 TGNGNTGNNT AAGGCCAGTG GGCCTGTAAT ACNTCTCACT ATAGGGCGAA  
51 TTGGGCCCTC TAGATGCATG CTCGAGCGGC CGCCAGTGTG ATGGATATCT  
101 GCAGAATTCG GCTTATTAAC CCTCACTAAA TGCTGGGTGN CTATNAAATA  
151 AAATACCTTA TAACATCCNT CTNAAAATCC GTAGATGGAG GAGACAAGAA  
201 CGACTAATNA ATATCAAATN CGGGCCNGTC NTCTCNATGT GTCTNACTCA  
251 NCANNGGCCA CTTGCTTCAT GCNAACNGGT CTGGGAGANG TGAANATCAC  
301 AGATGGACTC CAGGTCTCCA CACTAAGGAA GGCTGTCGCC CTCTGTCTAC 
351 NCATAAGATA TTCATCGGGT CTCCCTTNCA CATGGNCCAT GAATCATNGA  
401 GCCTGTGGGT AATNCCCCCG TTCACNGCCT ANAACCNANT TTANNCNNAC  
451 TTCTAANCTA NCTTCCTCAA T 
F o r w a r d  P r i m e r  : I 15 - 13d
BAND 18.Seq (P6T4)
LENGTH: 450
1 NCNGAGNNAT TGNCGTCGTA CAACTCTTCA CTATAGGGCG AATTGGGCCC  
51 TCTAAATGCA TGCTCGAGCG GCCGCCAGTG TGATGGATAT CTGCAGAATT 
101 CGGCTTA I T A  A C C C T C A C T A  A A T G C T G G G T  GNTATGTTTN TGGATGCCTC 
151 TCACGGNNCG NAGTNNCATN AAANCAANTG TGTGGAACGN NCGCCGAACN  
201 TNGTNGGTAA GGTTACCGAT NTNCNAGAAN GATNAANACT NGNNNNTTGN  
251 CAGGANCACN NCACCNNNNA CNGACCAGGG CCTTATACAT NGGAGNTCTC  
301 NNNTNTGAAA ACAGAGGGAC TGGCAATTGA CGTGATTGTG CTANATGCTA  
351 AATTGGTNCG TTNNAAACTG GGGGGTGGTG ANTGCTTATN CCTTCCGAGC 
401 ANANACGTGT TANATTTTTA ACTGGAAGAT CGCCGTCTCG ANTAATTGAN  
F o r w a r d  P r i m e r :  1 0 7  -  1 3 1
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